Theresa Firestone has officially disclosed her ownership of 76,879 shares in Helus Pharma Inc., where she holds the position of director. This filing is significant as it underscores her influence within the company and the pharmaceutical sector.
Firestone's recent filing, dated October 23, 2026, provides insight into her stake in Helus Pharma, a company engaged in pharmaceutical preparations. The disclosure is part of ongoing regulatory requirements that ensure transparency in ownership among corporate leaders.
Background
Firestone Theresa is associated with Helus Pharma Inc., which operates under the SIC code for pharmaceutical preparations. The company is based in Toronto, Canada, and has undergone recent changes, including a name change from Cybin Inc. in November 2020. This filing is part of her recent activities, with the latest filing being a Form 3 submitted on October 23, 2026.
What the Filing Says
According to the filing, Firestone currently owns 76,879 shares of common stock in Helus Pharma. The ownership is categorized as direct, meaning she holds the shares in her name, and it reflects her commitment to the company's future.
Impact
This disclosure may impact various stakeholders, including investors and other directors within Helus Pharma. As a director, Firestone's ownership stake could influence corporate governance and strategic decisions moving forward.
What's Next
The filing does not say what happens next.